BAX
Price
$17.69
Change
-$0.46 (-2.53%)
Updated
Nov 19 closing price
Capitalization
9.09B
84 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$10.08
Change
-$0.18 (-1.75%)
Updated
Nov 19 closing price
Capitalization
2.01B
98 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BAX vs XRAY

Header iconBAX vs XRAY Comparison
Open Charts BAX vs XRAYBanner chart's image
Baxter International
Price$17.69
Change-$0.46 (-2.53%)
Volume$7.69M
Capitalization9.09B
DENTSPLY SIRONA
Price$10.08
Change-$0.18 (-1.75%)
Volume$3.49M
Capitalization2.01B
BAX vs XRAY Comparison Chart in %
BAX
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BAX vs. XRAY commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and XRAY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (BAX: $17.69 vs. XRAY: $10.08)
Brand notoriety: BAX and XRAY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BAX: 105% vs. XRAY: 96%
Market capitalization -- BAX: $9.09B vs. XRAY: $2.01B
BAX [@Pharmaceuticals: Other] is valued at $9.09B. XRAY’s [@Pharmaceuticals: Other] market capitalization is $2.01B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $200.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 1 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • BAX’s FA Score: 1 green, 4 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, both BAX and XRAY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).

  • BAX’s TA Score: 5 bullish, 3 bearish.
  • XRAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BAX is a better buy in the short-term than XRAY.

Price Growth

BAX (@Pharmaceuticals: Other) experienced а -5.40% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -7.01% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.61%. For the same industry, the average monthly price growth was +0.60%, and the average quarterly price growth was +8.85%.

Reported Earning Dates

BAX is expected to report earnings on Feb 12, 2026.

XRAY is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-0.61% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BAX($9.09B) has a higher market cap than XRAY($2.01B). BAX YTD gains are higher at: -38.270 vs. XRAY (-45.090). BAX has higher annual earnings (EBITDA): 1.04B vs. XRAY (-689M). BAX has more cash in the bank: 1.69B vs. XRAY (1.27B). XRAY has less debt than BAX: XRAY (2.49B) vs BAX (9.73B). BAX has higher revenues than XRAY: BAX (10.9B) vs XRAY (3.67B).
BAXXRAYBAX / XRAY
Capitalization9.09B2.01B452%
EBITDA1.04B-689M-150%
Gain YTD-38.270-45.09085%
P/E Ratio87.85N/A-
Revenue10.9B3.67B297%
Total Cash1.69B1.27B133%
Total Debt9.73B2.49B390%
FUNDAMENTALS RATINGS
BAX vs XRAY: Fundamental Ratings
BAX
XRAY
OUTLOOK RATING
1..100
753
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9196
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
2683
SEASONALITY SCORE
1..100
536

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for BAX (77). This means that XRAY’s stock grew significantly faster than BAX’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that XRAY’s stock grew similarly to BAX’s over the last 12 months.

BAX's SMR Rating (91) in the Medical Specialties industry is in the same range as XRAY (96). This means that BAX’s stock grew similarly to XRAY’s over the last 12 months.

BAX's Price Growth Rating (65) in the Medical Specialties industry is in the same range as XRAY (65). This means that BAX’s stock grew similarly to XRAY’s over the last 12 months.

BAX's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for XRAY (83). This means that BAX’s stock grew somewhat faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXXRAY
RSI
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
52%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
38%
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 9 days ago
53%
Bullish Trend 29 days ago
56%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 1 day ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
48%
Bullish Trend 1 day ago
51%
Aroon
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
BAX
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FMAY52.050.04
+0.08%
FT Vest US Equity Buffer ETF May
BBAGF42.50N/A
N/A
BB Biotech AG
JUCY22.24-0.01
-0.04%
Aptus Enhanced Yield ETF
AADR82.93-0.04
-0.05%
AdvisorShares Dorsey Wright ADR ETF
BITW59.00-0.37
-0.62%
Bitwise 10 Crypto Index Fund

BAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ALGN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ALGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BAX
1D Price
Change %
BAX100%
-2.53%
ALGN - BAX
64%
Loosely correlated
+1.06%
LUNG - BAX
53%
Loosely correlated
-1.43%
STE - BAX
51%
Loosely correlated
-0.89%
SYK - BAX
51%
Loosely correlated
+1.31%
XRAY - BAX
47%
Loosely correlated
-1.75%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been closely correlated with NVST. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
-1.75%
NVST - XRAY
66%
Closely correlated
-0.94%
ALGN - XRAY
52%
Loosely correlated
+1.06%
AZTA - XRAY
51%
Loosely correlated
+2.07%
QDEL - XRAY
50%
Loosely correlated
-1.36%
SOLV - XRAY
50%
Loosely correlated
+0.55%
More